No matches
Type 2 Inflammation

Pediatric Asthma Trajectory and Clinical Remission

Join Dr. Leonard Bacharier as he discusses the definition of clinical remission in pediatric asthma and how it can represent a potential target in pediatric asthma management.
Leonard Bacharier
MD
Leonard Bacharier

Learning objectives

  • Understand the different criteria proposed for remission in pediatric asthma, including the role of oral corticosteroids and biomarkers
  • Recognize the factors influencing spontaneous remission in pediatric asthma

Description

In this video clip, from the ERS 2024 symposium, Dr. Leonard Bacharier discusses the concept of asthma remission and highlights the fluctuating nature of asthma activity in children.

Tags
pediatricasthmaremission
MAT-GLB-2503460 - 1.0 - 07/2025

About this expert

Allergy/Immunology
Pulmonology

Leonard Bacharier

MD

Janie Robinson and John Moore Lee Chair of Pediatrics and Director of Center for Pediatric Asthma Research | Vanderbilt University, Tennessee, United States

See author’s profile
Leonard Bacharier

Related resources

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission
Pulmonology
expert video

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma
Pulmonology
Podcast

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

Monitoring Lung Function Is an Important Aspect of Pediatric Asthma Management
Pulmonology
interactivity

Monitoring Lung Function Is an Important Aspect of Pediatric Asthma Management

On-Treatment Clinical Remission in Asthma Patients Case Tool
Pulmonology
interactivity

On-Treatment Clinical Remission in Asthma Patients Case Tool

Pediatric Asthma Patient Case Tool: Ash
Pulmonology
interactivity

Pediatric Asthma Patient Case Tool: Ash

Blood Eosinophils: A Biomarker in COPD
Pulmonology
Infographic

Blood Eosinophils: A Biomarker in COPD

A Triad of Interacting Mechanisms Driving the Pathophysiology of AD, Asthma, CRSwNP, and EoE
Type 2 Inflammation
Infographic

A Triad of Interacting Mechanisms Driving the Pathophysiology of AD, Asthma, CRSwNP, and EoE

Adult Asthma Interactive Patient Cases
Pulmonology
interactivity

Adult Asthma Interactive Patient Cases

Managing Type 2 Inflammatory Diseases: Multidisciplinary Frame of Mind
Type 2 Inflammation
expert video

Managing Type 2 Inflammatory Diseases: Multidisciplinary Frame of Mind

Clinical Manifestations Associated With Airway Remodeling in Asthma
Type 2 Inflammation
expert video

Clinical Manifestations Associated With Airway Remodeling in Asthma

Impact of Exacerbations in COPD
Type 2 Inflammation
expert video

Impact of Exacerbations in COPD

Exacerbations Lead to Worsening Lung Function
Type 2 Inflammation
expert video

Exacerbations Lead to Worsening Lung Function

2025 ADVENT Pulmonology/Rhinology Forum | Joint Plenary Session: A View into the Life of Our Patients Video
Type 2 Inflammation
expert video

2025 ADVENT Pulmonology/Rhinology Forum | Joint Plenary Session: A View into the Life of Our Patients Video

Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma
Type 2 Inflammation
expert video

Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma

Mucus Plugging as a Potential Target in Asthma Management
Type 2 Inflammation
expert video

Mucus Plugging as a Potential Target in Asthma Management

Multifaceted Role of IL-13 in Airway Remodeling
Type 2 Inflammation
expert video

Multifaceted Role of IL-13 in Airway Remodeling

Pediatric Asthma Trajectory and Clinical Remission
Type 2 Inflammation
expert video

Pediatric Asthma Trajectory and Clinical Remission

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: IndiaChange country/region